Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.

REGEN-COV (casirivimab/imdevimab) - Regeneron, Roche

bamlanivimab (LY-CoV555) - Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases

http://www.ncbi.nlm.nih.gov/pubmed/36704987

Jan 28, 2023